C-REGS2—A multinational, high-quality comparative effectiveness study of Cerebrolysin in moderate acute ischemic stroke
C-REGS2—Eine multinationale, hochwertige vergleichende Wirksamkeitsstudie zu Cerebrolysin bei moderatem akutem ischämischem Schlaganfall
International Journal of Stroke · 2025-10 · 20 (9) · 1060-1070
DOI: 10.1177/17474930251375439 ↗Auf einen Blick
C-REGS2 verglich Cerebrolysin mit Standardtherapie bei moderatem ischämischem Schlaganfall. Cerebrolysin war im primären Endpunkt und in allen sekundären Endpunkten überlegen.
Fragestellung
Ist Cerebrolysin bei moderatem akutem ischämischem Schlaganfall der Standardtherapie hinsichtlich der funktionellen Erholung überlegen?
Methode
Offene, prospektive vergleichende Wirksamkeitsstudie in 16 Ländern; Vergleich mit Standardtherapie; primärer Endpunkt: ordinale mRS nach 90 Tagen.
Ergebnisse
1769 Patient:innen in der Zielpopulation: 1021 mit Cerebrolysin, 748 Kontrollen. Primärer Endpunkt: MW 0,6157 (95 %-KI 0,5910–0,6404; P < 0,0001).
Schlussfolgerung der Autor:innen
Die Ergebnisse zeigten die Wirksamkeit und Sicherheit von Cerebrolysin bei moderatem akutem ischämischem Schlaganfall in der klinischen Routine.
Kernaussagen
- Primärer Endpunkt zugunsten von Cerebrolysin
- Auch alle sekundären Endpunkte waren überlegen
- Keine Unterschiede in Sicherheitsmaßen berichtet
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Stroke, online erschienen am 24.08.2025. Verfasst von Milan R Vosko und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Kepler University Hospital, Johannes Kepler University, Linz, Austria. Hauptthemen laut MEDLINE: Ischemic Stroke, Amino Acids, Neuroprotective Agents. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: EVER Neuro Pharma.
Themen: Schlaganfall
Abstract (Originalsprache)
Background
The main objective of the Cerebrolysin REGistry Study in Stroke 2 (C-REGS2) was to systematically record the routine clinical use of Cerebrolysin in patients with moderate ischemic stroke (IS) following the principles of a prospective controlled effectiveness study (CES) to compare its effectiveness in terms of functional recovery to patients treated with standard therapy alone.
Methods
C-REGS2 used an open-label, prospective controlled comparative effectiveness design aligning with the Target Trial Emulation Framework (TTEF) and the GRACE principles for high-quality observational studies based on the principles of high-quality comparative effectiveness research (HQCER) to capture treatment effects in clinical practice. The study was conducted in 16 countries worldwide between April 2018 and April 2024. Moderate IS was defined as baseline NIH Stroke Scale (NIHSS) score 8–15. Treatment modalities and concomitant medications were according to local standards. The methodology included rigorous pre-specified analysis and tight risk-based centralized monitoring, to ensure minimal enrollment bias, maximize data quality and overall reliability of trial results. The compared patient groups were standardized using a restricted cohort design and non-parametric multilevel stratification following the Good Research for Comparative Effectiveness (GRACE) principles. The primary endpoint was ordinal analysis of the modified Rankin Scale (mRS) at 90 days after stroke onset. Secondary endpoints were the ordinal NIH Stroke Scale (NIHSS) at day 21 and 90 after stroke onset, the ordinal mRS at 21 days after IS, the proportion of patients with excellent recovery (mRS 0–1) as well as the proportion of patients with functional independence (mRS 0–2) at 90 days after stroke onset and the ordinal analysis of Montreal Cognitive Assessment (MoCA) scale at 90 days after IS.
Results
Out of 1865 enrolled patients, the target population (TP) comprised 1769 patients (1021 Cerebrolysin-treated and 748 controls). The median NIHSS at baseline was 10.0. Median Cerebrolysin dose was 30 ml, median treatment duration was 10 days. Cerebrolysin was superior to standard therapy in the primary endpoint independently to prior thrombolysis (MW 0.6157; confidence interval (CI) 0.5910–0.6404; P < 0.0001) as well as in all secondary endpoints: mRS at day 21 (MW 0.6065, 95% CI 0.5811–0.6319, P < 0.0001), NIHSS at day 21 (MW 0.5792; 95% CI 0.5576–0.6008; P < 0.0001) and NIHSS at day 90 (MW 0.5781; CI 0.5561–0.6002; P < 0.0001). Additional pre-specified secondary endpoints (proportion of patients with excellent recovery and functional independence) showed moderate superiority for Cerebrolysin. The ordinal MoCA showed superiority for Cerebrolysin in the TP (MW 0.5530; CI 0.5282–0.5778; P < 0.0001) with more pronounced effects in the subgroup with cognitive impairments at baseline (Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) ⩾ 3.3). No differences in safety measures were recorded. The study is notable for its robust data integrity, with valid entries of 90.9% for the primary 90 day mRS assessment with multilevel case mix standardization and an overall dropout rate to the final visit of only 5.7%.
Conclusion
The results of the C-REGS2 study showed the effectiveness and safety of Cerebrolysin treatment for moderate acute IS in real-world clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Kepler University Hospital, Johannes Kepler University, Linz, Austria.
- Department of Neurology, Landesklinikum Amstetten, Amstetten, Austria.
- Department of Neurology, University Hospital Olomouc, Olomouc, Czech Republic.
- Department of Neurology, Daegu Catholic University Medical Center, Daegu, South Korea.
- Department of Internal Medicine, Perpetual Succour Hospital, Cebu City, Philippines.
- Department of Neurology, Ain Shams University, Cairo, Egypt.
ORCID-Profile: Milan R Vosko, Jarungchai S Vatanagul, Natan M Bornstein, Michael Brainin
Förderung
- EVER Neuro Pharma
Zitieren
APA
Vosko, M. R., Sanak, D., Do, Y., Vatanagul, J. S., Roushdy, T., Bornstein, N. M., Vester, J. C., & Brainin, M. (2025). C-REGS2—A multinational, high-quality comparative effectiveness study of Cerebrolysin in moderate acute ischemic stroke. International Journal of Stroke, 20(9), 1060-1070. https://doi.org/10.1177/17474930251375439
Vancouver
Vosko MR, Sanak D, Do Y, Vatanagul JS, Roushdy T, Bornstein NM, et al. C-REGS2—A multinational, high-quality comparative effectiveness study of Cerebrolysin in moderate acute ischemic stroke. International Journal of Stroke. 2025;20(9):1060-1070. doi:10.1177/17474930251375439
BibTeX
@article{Vosko2025,
author = {Vosko, Milan R and Sanak, Daniel and Do, Youngrok and Vatanagul, Jarungchai S and Roushdy, Tamer and Bornstein, Natan M and Vester, Johannes C and Brainin, Michael},
title = {C-REGS2—A multinational, high-quality comparative effectiveness study of Cerebrolysin in moderate acute ischemic stroke},
journal = {International Journal of Stroke},
year = {2025},
volume = {20},
number = {9},
pages = {1060--1070},
doi = {10.1177/17474930251375439}
}
EUVIMED